KR101797993B1 - Composition comprising crude drug of willow variant for treating, preventing or improvingcardiovascular disease - Google Patents
Composition comprising crude drug of willow variant for treating, preventing or improvingcardiovascular disease Download PDFInfo
- Publication number
- KR101797993B1 KR101797993B1 KR1020170072519A KR20170072519A KR101797993B1 KR 101797993 B1 KR101797993 B1 KR 101797993B1 KR 1020170072519 A KR1020170072519 A KR 1020170072519A KR 20170072519 A KR20170072519 A KR 20170072519A KR 101797993 B1 KR101797993 B1 KR 101797993B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- willow
- pine
- weight
- herbal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 241000124033 Salix Species 0.000 title claims abstract description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 13
- 201000010099 disease Diseases 0.000 title description 11
- 239000003814 drug Substances 0.000 title description 2
- 229940079593 drug Drugs 0.000 title 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 58
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 58
- 241000018646 Pinus brutia Species 0.000 claims abstract description 58
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 32
- 206010020772 Hypertension Diseases 0.000 claims abstract description 15
- 241000646858 Salix arbusculoides Species 0.000 claims abstract description 10
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 10
- 230000006793 arrhythmia Effects 0.000 claims abstract description 10
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 20
- 239000004615 ingredient Substances 0.000 claims description 19
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- 239000006187 pill Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 235000014066 European mistletoe Nutrition 0.000 claims description 6
- 244000152640 Rhipsalis cassutha Species 0.000 claims description 6
- 235000012300 Rhipsalis cassutha Nutrition 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- 241000121220 Tricholoma matsutake Species 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 244000131316 Panax pseudoginseng Species 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 235000021329 brown rice Nutrition 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 230000002363 herbicidal effect Effects 0.000 claims description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims 1
- 240000007890 Leonurus cardiaca Species 0.000 claims 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 239000007788 liquid Substances 0.000 abstract description 5
- 241000913743 Rhynchosia Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 34
- 241000411851 herbal medicine Species 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 208000019622 heart disease Diseases 0.000 description 12
- 230000008901 benefit Effects 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 241000371652 Curvularia clavata Species 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000254171 Curculionidae Species 0.000 description 2
- 241000123150 Fomitopsis pinicola Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000269400 Sirenidae Species 0.000 description 2
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 241001513212 Allium hookeri Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241000209134 Arundinaria Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241001463014 Chazara briseis Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000014493 Crataegus Nutrition 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000003271 Leonurus japonicus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 1
- 102100037838 Prolyl endopeptidase Human genes 0.000 description 1
- 101710178372 Prolyl endopeptidase Proteins 0.000 description 1
- 241000050850 Quercus nigra Species 0.000 description 1
- 240000008301 Rhynchosia minima Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- -1 diethyl Diethyl ether Chemical compound 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000071 effect on fever Effects 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002847 impedance measurement Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 버드나무 변이종의 생약 성분을 포함하는 심혈관계 질환의 치료, 예방 또는 개선용 조성물에 관한 것이다. The present invention relates to a composition for treating, preventing or ameliorating a cardiovascular disease comprising willow variant herbal ingredients.
생약이라 함은 자연으로부터 얻어지는 식물, 동물, 광물 및 미생물과 이들의 대사산물을 의약품으로 사용하기 위하여 이들을 절단, 분쇄, 추출 등의 간단한 가공을 통해 그 본질을 변화시키지 않은 상태의 천연물, 또는 이들로부터 약효 성분을 추출하여 사용하거나 정제를 만들어 사용하는 것들을 통칭하며, 천연물을 임상에 사용한 경험이 역사적으로 풍부한 국가인 우리나라와 중국, 일본 등에서 질병 치료에 사용되는 천연물을 생약이라 일컫는다.Herbal medicine means a natural product in which the nature of the plant, animal, mineral, microorganism, and metabolite obtained from nature is not changed through simple processing such as cutting, crushing, The term "herbal medicine" refers to the natural products used in the treatment of diseases in Korea, China, and Japan, which are historically rich countries that have used natural products for clinical purposes.
한편, 심혈관계는 혈액의 순환을 통하여 각 장기 세포의 활동에 필요한 산소, 영양소, 호르몬 등을 공급하여 주는 한편 각 세포에서 생성된 이산화탄소, 젖산 등의 노폐물을 제거하는 등 인체의 생리기능이 정상적으로 유지되도록 해준다. 심혈관계 질환(cardiovascular disease)은 우리나라에서 1970년대부터 주요 사망원인으로 등장하여 최근에는 사망원인1순위를 차지하고 있다. 심혈관게 질환은 심장질환 및 대동맥과 같은 중심혈관 및 말초혈관의 질환을 포함하는 심장혈관계에 이상이 온 질환을 총칭하며 고혈압, 고지혈증, 동맥경화증, 심근경색, 심부전, 부정맥, 협심증 등과 같은 질환군을 포함한다. On the other hand, the cardiovascular system supplies the oxygen, nutrients, and hormones required for the activity of each organ cell through the circulation of blood, while the physiological function of the human body is normally maintained, for example, by removing waste products such as carbon dioxide and lactic acid As well. Cardiovascular disease has been the leading cause of death in Korea since the 1970s and has recently become the leading cause of death. Cardiovascular disease is a disorder of the cardiovascular system including central and peripheral vascular diseases such as heart disease and aortic anomalies, and includes diseases such as hypertension, hyperlipidemia, atherosclerosis, myocardial infarction, heart failure, arrhythmia and angina .
상기 고혈압은 혈관이 받는 압력이 높은 상태를 의미하는 것으로, 만성 순환기계 질환 중 발생빈도가 가장 높은 질환으로 비교적 증상이 없으나 뇌, 심장, 신장, 눈 등 표적 장기의 손상으로 인한 심부전, 뇌출혈, 혈관 손상으로 인한 동맥경화, 뇌경색, 협심증, 심근경색과 같은 여러가지 합병증의 원인이 된다. 이 때, 혈압은 심장이 피를 내보내는 압력으로, 혈관의 유연성과 밀접한 관계가 있으며, 보통은 동맥혈압을 의미한다. 수축기 혈압이 120 ~ 130mmHg, 이완기 혈압이 80 ~ 85mmHg의 범위 안이면 정상혈압이라고 한다. 이와 달리 수축기 혈압이 135mmHg, 이완기 혈압이 80mmHg 이상인 경우를 고혈압이라고 한다.The hypertension refers to a state in which the pressure of the blood vessel is high, which is the highest incidence of chronic circulatory diseases and is relatively non-symptomatic. However, hypertension is caused by heart failure such as brain, heart, It causes various complications such as atherosclerosis, cerebral infarction, angina pectoris, and myocardial infarction. At this time, blood pressure is the pressure of the heart to discharge the blood, which is closely related to the flexibility of the blood vessel, and usually means arterial blood pressure. If the systolic blood pressure is in the range of 120 to 130 mmHg and the diastolic blood pressure is in the range of 80 to 85 mmHg, it is called normal blood pressure. In contrast, hypertension is defined as a systolic blood pressure of 135 mmHg and a diastolic blood pressure of 80 mmHg or greater.
일반적으로 심혈관계 질환의 개선 효과가 있는 것으로 알려진 아스피린의 주성분은 살리실산(salicylic acid)으로 이는 버드나무 껍질에서 추출되는 것으로 알려져 있다. 이 외에도, 버드나무 껍질을 달여 마시면 감기나 신경통 등에 효과가 있으며 구체적으로 진통 및 해열에 효과가 있는 것으로 알려져 있다. It is known that salicylic acid is the main component of aspirin, which is generally known to improve cardiovascular disease, which is extracted from willow bark. In addition, if you drink willow bark on the month of the cold or neuralgia is effective and is known to have an effect on pain and fever specifically.
이와 같은 사실을 바탕으로, 대한민국 등록특허 제10-0826672호에는 뽕나무와 버드나무를 주재료로 포함하며, 고혈당 및 고혈압에 효과가 있는 건강음료 및 이의 제조방법에 대하여 기재되어 있으나, 심혈관계 질환에 대한 효과는 다소 부족하여 여전히 개선의 여지가 있는 실정이었다.Based on these facts, Korean Patent No. 10-0826672 discloses a health drink containing mulberry and willow as main ingredients and a method for producing hyperglycemia and hypertension, and a method for producing the same, The effect was somewhat lacking and there was still room for improvement.
본 발명은 상기와 같은 문제를 해결하기 위한 것으로서, 심혈관계 질환에 대한 개선 또는 치료 효과가 우수한 조성물을 제공하는 것을 그 목적으로 한다. Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made to solve the above-mentioned problems, and it is an object of the present invention to provide a composition which is excellent in improvement or therapeutic effect on cardiovascular diseases.
상기 목적을 달성하기 위한 본 발명의 심혈관계 질환 치료, 예방 또는 개선용 조성물은 버드나무 변이종(꽃잎버들)의 생약성분을 포함하는 것을 특징으로 한다. To achieve the above object, the present invention provides a composition for treating, preventing or ameliorating cardiovascular diseases, comprising a herbal composition of willow varieties.
또한, 본 발명의심혈관계 질환 치료, 예방 또는 개선용 조성물의 제조방법은 버드나무 변이종 및 서목태를 각각 분쇄하여 분쇄물을 얻는 단계(1공정); 상기 1공정의 각 분쇄물을 서로 혼합하고, 상기 혼합물에 솔잎 내지 송순 발효액을 섞어 반죽하는 단계(2공정); 및 상기 2공정의 반죽으로 환을 만들어 건조하는 단계(3공정);를 포함하는 것을 그 특징으로 한다.In addition, the method for preparing a composition for treating, preventing or improving a susceptible vascular disease according to the present invention comprises the steps of (1) obtaining a pulverized product by pulverizing a willow variant and a western blot; Mixing the respective pulverized products of the one step with each other and kneading the mixture with a pine needle or a pine needle fermentation liquid (step 2); And a step of drying the kneaded dough of the two steps and drying (step 3).
또한, 본 발명의 심혈관계 질환 개선 또는 예방용 건강기능식품은 버드나무 변이종의 생약성분을 포함하는 것을 특징으로 한다.In addition, the health functional food for improving or preventing cardiovascular diseases of the present invention is characterized by containing a herbal composition of willow variant.
본 발명의 심혈관계 질환 치료, 예방 또는 개선용 조성물은 버드나무 변이종의 생약 성분을 포함함으로써, 심혈관계 질환에 대한 개선 또는 치료 효과가 우수한 이점이 있다. The composition for treating, preventing or improving cardiovascular diseases according to the present invention has an advantage of improving or treating cardiovascular diseases by containing herbal ingredients of willow variant.
또한, 본 발명의 심혈관계 질환 치료, 예방 또는 개선용 조성물의 제조방법은 전술한 조성물을 환의 형태로 제조함으로써 취급 및 보관이 용이한 이점이 있다.In addition, the method for preparing a composition for treating, preventing or improving cardiovascular diseases of the present invention is advantageous in that it can be easily handled and stored by producing the above-described composition in the form of a ring.
또한, 본 발명의 심혈관계 질환 개선 또는 예방용 건강기능식품은 버드나무 변이종의 생약성분을 포함함으로써, 심혈관계 질환에 대한 개선 또는 예방 효과가 우수한 이점이 있다. In addition, the health functional food for improving or preventing cardiovascular diseases of the present invention has an advantage of improving or preventing cardiovascular diseases by containing a herbal medicine component of willow variant.
도 1의 (a)는 버드나무 변이가 일어나기 시작한 초기의 모습에 대한 이미지이다.
도 1의 (b)는 버드나무 변이가 진행중인 중기의 모습에 대한 이미지이다.
도 1의 (c)는 버드나무 변이가 완료된 말기의 모습에 대한 이미지이다.
도 2는 변이가 일어나지 않은 버드나무 잎에 대한 이미지이다.
도 3은 본 발명의 일 실시예로서 제조된 환제에 대한 이미지이다.Fig. 1 (a) is an image of an initial appearance of a willow variation.
Fig. 1 (b) is an image of the mid-stage of a willow variation.
FIG. 1 (c) is an image of the state of the last stage when the willow mutation is completed.
Fig. 2 is an image of a willow leaf that has not undergone mutation.
Figure 3 is an image of a pillow manufactured as one embodiment of the present invention.
이하, 본 발명에 대하여 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 한 양태에 따른 심혈관계 질환 치료, 예방 또는 개선용 조성물은 버드나무 변이종(일명 꽃잎버들)의 생약성분을 포함하는 것을 포함함으로써, 고혈압, 고지혈증, 동맥경화증, 심근경색, 심부전, 부정맥, 협심증 등의 심혈관계 질환의 증상에 대한 개선 또는 치료효과가 우수한 이점이 있다. The composition for treating, preventing or ameliorating a cardiovascular disease according to an embodiment of the present invention includes a herbal composition of willow variant (aka petal weevil), and thus can be used for treatment of hypertension, hyperlipidemia, arteriosclerosis, myocardial infarction, heart failure, arrhythmia, Angina pectoris and the like.
본 발명에서 버드나무 변이종이란 갯버들, 키버들 등의 2 내지 5m 높이의 작은 버드나무 종의 나뭇잎이 겹벚꽃 형태로 변이된 버드나무(도 1 참조)를 의미한다. 상기 버드나무 변이종은 낙엽이 지는 시기(약 10월 ~ 12월)에 색의 변화가 뚜렷하게 나타나는데, 변이가 일어나지 않은 버드나무의 낙엽색보다 진하고 어두운 갈색(흑갈색)으로 색이 변하기 때문에 그 시기에 변이종의 발견이 보다 용이하다. 상기와 같은 형태의 버드나무 변이종에 대해서는 그 발생원인이 아직 명확하지 않으며, 이에 대한 학명 또한 알려진 바 없는 희귀한 종이다. 또한, 이와 같은 변이는 일반적으로 생약으로 많이 사용되는 약재의 원료인 수양버들, 능수버들, 왕버들 등의 큰 버드나무 종류에서는 발생하지 않는다. 이에 본 출원인은 상기와 같은 버드나무 변이종에 대한 연구를 시작하였고, 상기 버드나무 변이종이 변이가 일어나지 않은 버드나무(도 2 참조)보다 혈액을 맑게 해주는 약성이 탁월하여 혈액 내의 고지혈을 제거하는 등의 효과가 우수할 뿐만 아니라, 심장의 혈전을 제거하여 심장병(부정맥, 협심증 등)과 고혈압 등 심혈관계 질환의 치료, 예방 및 개선에 탁월한 효과가 있는 것을 확인하여 본 발명을 완성하였다. 이 때, 버드나무 변이종을 사용하게 될 경우, 변이가 일어난 종에 대해서는 1년 내내 어느 시기에 사용하여도 그 효과는 동일한 것으로 밝혀졌으며, 예를 들면 아직 색의 변화가 일어나지 않은 시기에 버드나무 변이종을 사용하여도 기대되는 효과는 동일하다. In the present invention, the willow variant is a willow (see Fig. 1) in which leaves of a small willow species 2 to 5 m high, such as pussy beds, key birds, etc., are mutated into a double cherry tree form. In the willow variant, the color change is noticeable at the time of fallen leaves (about October to December), but the color changes to darker dark brown (dark brown) than that of willow tree where no mutation occurs. Discovery is easier. The cause of this type of willow mutant is not clear yet, and its scientific name is also unknown. Such variations do not occur in large willow species such as canes, bean curds, and wolves, which are commonly used as raw materials for medicinal materials commonly used as herbal medicines. Thus, the applicant of the present invention has studied the above-mentioned Willow variant and found that the Willow variant is superior to the Willow (see FIG. 2) in which the mutation did not occur and clears the blood, thereby eliminating hyperhidrosis in the blood The present invention has been accomplished on the basis of not only an excellent effect but also an excellent effect in the treatment, prevention and improvement of cardiovascular diseases such as heart disease (arrhythmia, angina pectoris and the like) and hypertension by removing the thrombus of the heart. At that time, when the willow variant was used, the effect was found to be the same regardless of the time of year throughout the year for the variant species. For example, at the time when no color change occurred, The expected effects are the same.
본 발명에서 의미하는 버드나무 변이종의 생약성분이란 상기 버드나무 변이종의 줄기, 가지, 껍질, 잎, 뿌리 등 버드나무의 여러 천연부위 자체, 또는 이의 건조물 또는 추출물을 의미할 수 있다. The term "herb medicine composition" as used in the present invention may refer to various natural parts of willow such as stem, branch, bark, leaf, and root of willow tree mutant, or dried or extract thereof.
본 발명의 일 실시형태에 따르면, 상기 버드나무 변이종의 생약성분의 함량은 이를 포함하는 조성물 전체 100중량%에 대하여, 40 내지 70중량%로 포함될 수 있으며, 바람직하게는 50 내지 70중량%로 포함될 수 있다. 상기 버드나무 변이종의 생약성분의 함량이 상기 범위를 만족하는 경우, 심혈관계 질환을 보다 효과적으로 개선할 수 있는 이점이 있다. According to one embodiment of the present invention, the content of the herbal composition of willow variant may be 40 to 70% by weight, preferably 50 to 70% by weight, based on 100% by weight of the total composition . When the content of the herbal composition of the willow variant satisfies the above range, there is an advantage that the cardiovascular disease can be more effectively improved.
본 발명의 일 실시형태에 따른 심장질환 치료, 예방 또는 개선용 조성물은 솔잎 내지 송순 발효액 및 서목태로 이루어진 군으로부터 선택되는 하나 이상의 생약성분을 더 포함할 수 있다. 이 때, 상기 생약성분이란 약용 식물의 천연부위 자체, 또는 이의 건조물 또는 추출물을 의미할 수 있다. The composition for treating, preventing or improving a heart disease according to an embodiment of the present invention may further comprise at least one herbal medicine ingredient selected from the group consisting of pine needle, Here, the herbal medicine component may mean the natural part of the medicinal plant itself, or a dried product or an extract thereof.
상기 솔잎 내지 송순은 동맥경화, 고혈압, 두통, 협심증, 중풍, 신경통, 산후풍 등 다양한 질병의 건강식품 및 치료제로 사용되는 있는 것으로, 주로 적송 등 재래종 소나무인 2엽송이 약용식물로써 사용될 수 있다. 상기 솔잎 내지 송순에는 송진이 함께 포함되어 있는데, 이 때 송진은 인체에 들어가면 배출이 되지 않고 혈관 내에 침착되어 다양한 질환을 야기할 수 있다. 따라서, 본 발명에서는 상기와 같은 솔잎 내지 송순을 발효액의 형태로 제조한 후 떠오르는 송진을 제거하는 과정을 거침으로써 송진이 인체에 투입되는 것을 방지하였다. The pine needle or pine needle can be used as a health food and remedy for a variety of diseases such as arteriosclerosis, hypertension, headache, angina pectoris, paralysis, neuralgia, and arthropod. When the pine needles are inserted into the human body, the pine needles may be deposited in the blood vessels to cause various diseases. Accordingly, in the present invention, the above-described pine needle or pine cone is prepared in the form of a fermentation broth, and then the rising pine nut is removed to prevent the feeding of the pine nut to the human body.
본 발명의 일 실시형태에 따르면 상기 솔잎 내지 송순은 1년 미만의 것이 사용될 수 있다. 1년 미만의 솔잎 내지 송순을 사용할 경우 잎이 연하고 솔잎 내지 송순 내부에 존재하는 진액이 풍부하여 발효액 제조에 유리한 이점이 있다.According to one embodiment of the present invention, the pine needle or the pine needle can be used for less than one year. When the pine needle or pine needle is used for less than one year, there is an advantage of producing a fermentation broth because the leaf is soft and the pine needle exists in the pine needle or the pine mushroom.
본 발명의 일 실시형태에 따르면 상기 솔잎 내지 송순의 발효액은 솔잎 내지 송순을 잘게 써는 제1단계 상기 제1단계의 잘게 썬 솔잎 내지 송순에 설탕을 1:1 중량비율로 섞은 후 녹여서 솔잎 내지 송순 및 설탕 혼합물을 얻는 제2단계 상기 제2단계의 솔잎 내지 송순 및 설탕의 혼합물을 3개월 내지 6개월 동안 발효시켜 발효액을 얻는 제3단계 및 상기 제3단계의 발효액을 걸러 송진을 제거하는 제4단계를 포함하여 제조될 수 있다. 이 때, 상기 제3단계의 발효과정은 실온에서 실시될 수 있다.According to one embodiment of the present invention, the fermentation broth of pine needles or pine cones is prepared by finely pilling pine needles or pine nuts. The first step is to mix the finely chopped pine needles or pine nuts in the first step with sugar at a weight ratio of 1: 1, A second step of obtaining a fermentation broth by fermenting the mixture of pine needle, pine nuts and sugar in the second step for 3 months to 6 months, and a third step of filtering the fermented broth of the third step and removing the rosin . ≪ / RTI > At this time, the fermentation process of the third step may be performed at room temperature.
본 발명의 심장질환 치료, 예방 또는 개선용 조성물이 상기 솔잎 내지 송순의 발효액을 포함할 경우 그 함량은 이를 포함하는 조성물 전체 100중량%에 대하여, 10 내지 25중량%, 바람직하게는 10 내지 20중량%로 포함될 수 있다. 상기 솔잎 내지 송순의 발효액의 함량이 상기 범위를 만족하는 경우 심혈관계 질환을 효과적으로 예방할 수 있을 뿐만 아니라, 함께 포함되는 건조한 가루 형태의 다른 생약 성분들에 적절한 점성을 부여하여 하나의 형태로 결합시킬 수 있는 이점이 있다.When the composition for treating, preventing or ameliorating a heart disease of the present invention comprises the fermentation broth of pine needle or tongue, the content thereof is preferably 10 to 25% by weight, more preferably 10 to 20% by weight %. ≪ / RTI > When the content of the fermentation broth of the pine needle or the pine nugget satisfies the above range, not only the cardiovascular diseases can be effectively prevented, but also the other herbal ingredients in the dry powder form contained therein can be bonded in one form There is an advantage.
상기 서목태(Rhynchosia nulubilis)는 해독성이 탁월하고 섬유질이 많아 장의 활성화에 기여할 수 있다. 또한, 신장병을 다스리며 기를 내리어 모든 풍열을 억제하고 혈액을 활발히 하며 독을 풀어주는 효과가 있다. 서목태의 껍질의 검은색은 신장치유에 좋은 효능이 있으며, 속 알맹이의 푸른색은 간장 치유에 좋은 효능이 있으며, 이와 같은 서목태는 고혈압, 당뇨, 고지혈증과 같은 성인병 치료에 효과가 있다. 또한, 상기 서목태를 함께 포함하는 경우 서목태의 점성으로 인하여 함께 포함되는 건조한 다른 생약성분들을 하나의 형태로 결합시키는 것이 가능한 이점이 있으며, 그 해독작용을 이용하여 버드나무 생약성분에 남아있을지 모르는 독성을 중화시킬 수 있는 이점이 있다.Rhynchosia nulubilis is excellent in detoxification and has a large amount of fiber, which can contribute to the intestinal activation. Also, it has the effect of controlling all kinds of fever, activating blood and releasing poison by controlling the kidney disease and lifting the base. The black color of Seomoktae's skin is good for healing the kidneys. The blue color of the pellets is good for the healing of the liver, and it is effective for treating geriatric diseases such as hypertension, diabetes and hyperlipemia. In addition, when the present invention is combined with other ingredients, it is possible to combine other dry herbicidal ingredients contained together due to the viscosity of the present invention, and it is possible to use the detoxifying action to inhibit the toxicity There is an advantage that it can be neutralized.
본 발명의 심장질환 치료, 예방 또는 개선용 조성물이 상기 서목태의 생약성분을 포함하는 경우, 그 함량은 이를 포함하는 조성물 전체 100중량%에 대하여 10 내지 25중량%로 포함될 수 있으며, 바람직하게는 10 내지 20중량%로 포함될 수 있다. 상기 서목태의 생약 성분의 함량이 상기 범위 내로 포함되는 경우 혈액 순환을 활발히 하는 효과를 충분히 발휘하면서, 함께 포함되는 다른 성분들의 함량 범위 또한 침해하지 않는 이점이 있다.When the composition for treating, preventing or ameliorating a heart disease of the present invention contains the herbal composition of the present invention, the content thereof may be 10 to 25% by weight based on 100% by weight of the total composition, preferably 10 To 20% by weight. When the content of the herbal medicine ingredient in the above-mentioned formulas is within the above-mentioned range, there is an advantage that the content range of the other ingredients included together is not infringed while fully exercising the effect of activating blood circulation.
본 발명의 일 실시형태에 따른 심장질환 치료, 예방 또는 개선용 조성물은 또한, 산사자 및 삼채로 이루어진 군으로부터 선택되는 하나 이상의 생약 성분을 더 포함할 수 있다. 이 때, 상기 생약성분이란 약용 식물의 천연부위 자체, 또는 이의 건조물 또는 추출물을 의미할 수 있다.The composition for treating, preventing or ameliorating a heart disease according to an embodiment of the present invention may further comprise at least one herbal medicine ingredient selected from the group consisting of a spermatozoa and a triplet. Here, the herbal medicine component may mean the natural part of the medicinal plant itself, or a dried product or an extract thereof.
상기 산사자(Crataegus fruit)는 산사나무의 열매로 늦가을에 채취하여 약용으로 사용될 수 있다. 상기 산사자는 건위약으로 소화흡수 기능증진과 과식으로 인한 체증치료에 탁월한 효과가 있어 주로 위장질환(식욕부진, 소화불량, 복통), 변비, 설사 등의 치료제로 쓰일 수 있으며 또한, 심근의 기능을 강화시키며 혈액순환을 좋게하는 효과가 있어 심혈관계 질환(강심제, 심장쇠약, 혈압상승, 동맥경화, 부정맥, 협심증)을 개선 또는 치료하는 데에도 사용될 수 있으며, 버드나무의 생약성분 복용으로 인해 발생할 수 있는 위 점막 손상을 예방하는 효과가 있다. Crataegus fruit is a fruit of hawthorn tree and can be taken medically in late fall. The above-mentioned mountain sick person is excellent for treating digestive absorption and hyperactivity due to dryness, and can be used as a treatment for gastrointestinal diseases (anorexia, indigestion, abdominal pain), constipation and diarrhea. And can be used to improve or treat cardiovascular diseases (cardiovascular diseases, heart failure, hypertension, arteriosclerosis, arrhythmia, angina pectoris) and can be caused by taking herbal medicine of willow It is effective to prevent gastric mucosal damage.
본 발명의 심장질환 치료, 예방 또는 개선용 조성물이 상기 산사자의 생약성분을 포함하는 경우, 그 함량은 이를 포함하는 조성물 전체 100중량%에 대하여, 10 내지 15중량%로 포함될 수 있다. 상기 산사자의 함량이 상기 범위 내로 포함될 경우, 함께 포함되는 다른 성분들의 함량 범위를 침해하지 않으면서 산사자의 심혈관계 질환 개선 효과 또한 충분히 발휘할 수 있는 이점이 있다. When the composition for treating, preventing or ameliorating a heart disease of the present invention comprises a herbal composition of the present invention, its content may be 10 to 15% by weight based on 100% by weight of the total composition. When the content of the mountain sirens is within the above range, there is an advantage that the effect of improving the cardiovascular diseases of the sirens can be sufficiently exerted without infringing the content range of the other ingredients included together.
상기 삼채(Allium hookeri)는 파속(Allium) 식물로 단맛, 쓴맛, 매운맛이 난다고 하여 삼채(三菜)라고 부르며 인삼 맛이 난다고 하여 삼채(蔘菜)라고 부르기도 한다. 함황화물과 페놀성 화합물 함량이 높은 기능성 채소로 알려져 있으며, 다양한 질환 및 암 질환 등에 사용될 수 있고, 특히 삼채의 매운맛은 폐장에, 쓴맛은 심장질환에, 단맛은 비장과 위장 질환에 효능이 있다고 알려져 있다. Allium hookeri is an Allium plant. It is called "三 菜" because it has a sweet, bitter, and pungent taste. It is also called "玄 菜" because it is said to have ginseng flavor. It is known to be a functional vegetable with a high content of sulfoxides and phenolic compounds. It can be used for various diseases and cancer diseases. Especially, it is known that the flavor of tripe is effective for lung, bitter heart disease and sweet taste for spleen and gastrointestinal diseases have.
본 발명의 심장질환 치료, 예방 또는 개선용 조성물이 상기 삼채의 생약성분을 포함하는 경우, 그 함량은 이를 포함하는 조성물 전체 100중량%에 대하여, 10 내지 15중량%로 포함될 수 있다. 상기 삼채의 함량이 상기 범위 내로 포함될 경우, 함께 포함되는 다른 성분들의 함량 범위를 침해하지 않으면서 삼채의 심장질환 개선 또는 치료 효과 또한 충분히 발휘할 수 있는 이점이 있다.When the composition for treating, preventing or ameliorating a heart disease of the present invention comprises the herbal composition of the above-mentioned triplex, the content thereof may be 10 to 15% by weight based on 100% by weight of the composition containing the herbal composition. When the content of the triangle is included within the above range, there is an advantage that the effect of improving or treating the heart disease of the trichome can be sufficiently exerted without infringing the content range of the other components included together.
본 발명의 일 실시형태에 따른 심장질환 치료, 예방 또는 개선용 조성물은 또한, 전술한 성분들 이외에 익모초, 겨우살이, 목이, 소나무 잔나비버섯 및 발아흑미로 이루어진 군으로부터 선택되는 하나 이상의 생약 성분을 더 포함할 수도 있다. 이 때, 상기 생약성분이란 약용 식물의 천연부위 자체, 또는 이의 건조물 또는 추출물을 의미할 수 있다.The composition for treating, preventing or ameliorating a heart disease according to an embodiment of the present invention may further comprise at least one herbal medicine ingredient selected from the group consisting of motherhood, mistletoe, throat, pine mushroom and germinated brown rice in addition to the above- You may. Here, the herbal medicine component may mean the natural part of the medicinal plant itself, or a dried product or an extract thereof.
상기 익모초(Chinese motherwort)는 두해살이풀로 여름, 가을에 싹을 틔워 자라다가 이듬해 봄부터 왕성하게 성장하는 식물로, 주로 여성질환(무월경, 생리통, 산후 자궁 수축 불량으로 출혈, 자궁수축)에 효과가 좋을 뿐 아니라, 혈전 용해 작용, 심장과 관상 동맥 혈류량 증가 등의 효과가 있는 것으로 알려져 있다. The Chinese motherwort is a biennial plant that grows spontaneously in the summer and autumn, and grows vigorously from the spring of next year. It is mainly used for female diseases (amenorrhea, menstrual pain, poor postpartum uterine contraction, bleeding and uterine contraction). Not only is it good, but it is known to have effects such as thrombus dissolution, increased heart and coronary blood flow.
상기 겨우살이는 주로 키가 큰 나무에 기생하여 자라며 겨울에 채취할 수 있다. 상기 겨우살이는 고혈압, 당뇨, 중풍, 심장병 등 성인질환에 효과가 좋은 것으로 알려져 있다. The mistletoe grows mainly on a tall tree and can be harvested in winter. The mistletoe is known to be effective for adult diseases such as hypertension, diabetes, stroke and heart disease.
상기 목이는 목이과의 버섯으로, 주로 여름에서 가을에 걸쳐 물참나무, 너도밤나무 등의 활엽수의 고목에 군생한다. 상기 목이는 콜레스테를 수치를 낮춰 주는 등 혈관 내 노폐물을 제거할 수 있는 효과가 있으며 이로 인해, 혈전과 동맥 경화 의 개선 또는 예방에 효과가 있는 것으로 알려져 있다.The throat is a mushroom of the throat, and it grows in the tree of the hardwood such as the water oak, the beech tree mainly from the summer to the fall. The throat has the effect of removing the waste matter in the blood vessel such as lowering the level of cholesterol and is known to be effective in improving or preventing thrombosis and arteriosclerosis.
상기 소나무잔나비버섯(Fomitopsis pinicola)은 진균류에 속하는 담자균류 버섯 중 민주름버섯목 구멍장이 버섯과 잔나비버섯속에 속하며, 소나무뿐만 아니라 각종 침엽수의 고목 또는 생목의 줄기에도 자생한다. 자루가 없고 갓은 나무줄기에 선반모양으로 붙어서 반원형을 이루며, 상단부분은 두꺼운 각피로 덮여 있어 단단하고, 버섯 갓 둘레 부분에 적갈색의 띠가 둘러져 있으며, 밀면은 황백색으로 미세한 관공이 밀포된 특징을 가지고 있다. 이러한 소나무잔나비버섯은 멸종된 우리나라 자생버섯으로 알려져 있으나, 최근 한 농민에 의하여 새롭게 '소나무 재생버섯(Fomitopsis pinicola Jeseng)'으로 명명되고, 국립종자관리소에 등록(출원번호: 2003-498)된 버섯이다. 상기 소나무 잔나비버섯은 당뇨 합병증 에방, 당뇨 유도성 고콜레스테를 혈증 개선, 활성 산소 억제 등에 효과가 우수한 것으로 알려져 있다. The above-mentioned Fomitopsis pinicola belongs to the fungi belonging to the fungi belonging to the mushroom and manganese mushroom, and grows not only in the pine but also in the stem and the stem of the various coniferous trees. There is no bag, and the gut is attached to the tree trunk in the form of a shelf to form a semicircle. The upper part is covered with a thick cornice. It is hard and has a reddish brown band around the mushroom's shoulders. Have. These pine mushrooms are known to be endemic Korean native mushrooms, but recently mushrooms have been newly designated by the farmers as 'Fomitopsis pinicola Jeseng' and registered in the National Seed Management Office (Application No. 2003-498) . It is known that the pine forest mushroom has excellent effects on diabetic complications, diabetic induced hypercholesterolemia, and active oxygen inhibition.
상기 발아흑미(찹쌀)는 적당한 온도와 수분, 산소 등을 공급해 흑미의 싹을 1~5mm까지 발아시킨 것으로 흑미의 영양과 기능을 극대화 시키면서 식감은 일반 흑미보다 훨씬 부드러운 쌀이다. 구체적으로, 흑미가 발아하면 필수아미노산인 라이신(lysine), 고혈압, 동맥경화 등의 심혈관계 질환을 예방해주는 GABA(gamma-aminobutyric acid), 항암 작용이 뛰어난 아라비녹실란(arabinoxylane), 치매 예방에 효과적인 PEP(prolyl endopeptidase) 등이 크게 증가하며, 또한 암 예방 효과를 지닌 피틴산(IP6)은 미네랄과의 결합이 분리되면서 체내 흡수가 용이해지는 이점이 있다. The germinated black rice (glutinous rice) is germinated by 1 ~ 5mm of germination of black rice by supplying proper temperature, moisture and oxygen. It maximizes the nutrition and function of black rice, and the texture is much smoother than ordinary black rice. Specifically, when germination of black rice germinates, lysine which is an essential amino acid, GABA (gamma-aminobutyric acid) which prevents cardiovascular diseases such as hypertension and arteriosclerosis, arabinoxylane which has excellent anticancer activity, PEP prolyl endopeptidase and the like, and phytinic acid (IP6), which has a cancer-preventing effect, has an advantage of being easily absorbed into the body by separating its binding with minerals.
전술한 생약성분들이 건조물의 형태로 사용될 경우, 각 생약성분들을 깨끗하게 씻은 후 햇볕에 물기가 모두 빠지게 말리고, 따뜻한 방에서 2 ~ 3일간 바짝 말려 사용되는 것일 수 있으나, 건조물의 제조 방법과 관련한 내용은 본 발명에서는 특별히 한정하지 않는다. When the above-mentioned herbal ingredients are used in the form of a dried product, they may be used to dry each herbal composition cleanly, to dry off all the water in the sun, and to be dried for 2 to 3 days in a warm room. But the present invention is not particularly limited thereto.
또는 전술한 생약성분들이 추출물의 형태로 사용될 경우, 추출방법은 공지된 방법을 제한 없이 사용할 수 있다. 예를 들어, 냉침추출, 열수추출, 초음파 추출, 환류냉각 추출, 가열 추출법 등을 들 수 있으며, 바람직하게는 열수추출 또는 환류 냉각 추출법으로 추출될 수 있고, 1 회 내지 10회, 바람직하게는 2회 내지 7회 반복 추출할 수 있다. Or when the above-mentioned herbal ingredients are used in the form of an extract, the extraction method can be used without limitation in known methods. For example, the extract may be extracted by hot water extraction or hot water extraction, hot water extraction, ultrasonic extraction, reflux cooling extraction, heat extraction and the like, preferably by hot water extraction or reflux cooling extraction, It can be repeatedly extracted seven times or seven times.
추출용매는 물, 탄소수 1 내지 6의 유기용매 및 아임계 또는 초임계 유체로 이루어진 군에서 선택되는 하나 이상의 용매일 수 있으며, 구체적으로 상기 탄소수 1 내지 6의 유기용매는 탄소수 1 내지6의 알코올(alcohol), 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane), 시클로헥산(cyclohexane), 디에틸에테르(diethyl ether) 및 석유에테르(petroleum ether)로 이루어진 군 중에서 선택된 것일 수 있다. 바람직하게는 물 또는 탄소수 1 내지 6의 알코올을 사용할 수 있으나, 이에 한정되는 것은 아니다. The extraction solvent may be at least one solvent selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms and a subcritical or supercritical fluid. Specifically, the organic solvent having 1 to 6 carbon atoms may be an alcohol having 1 to 6 carbon atoms alcohol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, diethyl Diethyl ether, and petroleum ether. Preferably, water or an alcohol having 1 to 6 carbon atoms can be used, but is not limited thereto.
상기 추출물은 추출효율을 증대시키기 위해 전처리 과정을 포함할 수 있으며, 예를 들어, 각 생약성분을 분쇄기로 분쇄하여 사용할 수 있다. The extract may include a pretreatment step for increasing the extraction efficiency. For example, each of the herbal ingredients may be pulverized by a pulverizer.
상기 추출물의 추출온도는 특별히 한정되지 않으며, 예를 들어 0 내지 150℃일 수 있고, 바람직하게는 80 내지 120℃일 수 있다. 또한, 추출시간은 추출 온도에 따라 조절되는 것이므로 특별히 제한되지 않으나, 예를 들면 1시간 내지 10일일 수 있고, 바람직하게는 1시간 내지 6시간, 보다 바람직하게는 1시간 내지 3시간일 수 있다.The extraction temperature of the extract is not particularly limited and may be, for example, 0 to 150 ° C, preferably 80 to 120 ° C. The extraction time is not particularly limited as it is controlled according to the extraction temperature, but may be, for example, 1 hour to 10 days, preferably 1 hour to 6 hours, more preferably 1 hour to 3 hours.
본 발명의 일 실시형태에 따르면, 전술한 조성물은 심혈관계 질환 치료 또는 예방용 약학적 조성물일 수 있다. According to one embodiment of the present invention, the above-mentioned composition may be a pharmaceutical composition for treating or preventing cardiovascular diseases.
전술한 본 발명의 조성물 또는 약학적 조성물은 경구 또는 비경구적으로 투여될 수 있다. 비경구적인 투여방법으로는 정맥내, 근육내, 동맥내, 골수내, 경막내, 심장내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장내 투여 등을 들 수 있으나, 이에 한정되는 것은 아니다.The above-described composition or pharmaceutical composition of the present invention can be administered orally or parenterally. Parenteral administration methods include intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal administration, But is not limited thereto.
본 발명의 조성물 또는 약학적 조성물은 전술한 바와 같은 투여 경로에 따라 경구 투여용 또는 비경구 투여용 제제로 제형화 할 수 있다. The composition or pharmaceutical composition of the present invention can be formulated into oral or parenteral dosage forms according to the route of administration as described above.
상기 경구투여를 위한 고형제제는 분말, 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며 이들은 당업계에 공지된 방법을 이용하여 제형화될 수 있다. 이러한 고형 제제는 상기 조성물 또는 약학적 조성물에 적어도 하나 이상의 부형제를 배합하여 사용될 수 있다. 상기 부형제는 예를 들면, 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨 및 말티톨 등을 포함하는 당류와 옥수수 전분, 밀 전분, 쌀 전분 및 감자 전분 등을 포함하는 전분류, 셀룰로즈, 메틸 셀룰로즈, 나트륨 카르복시메틸셀룰로오즈 및 하이드록시프로필메틸-셀룰로즈 등을 포함하는 셀룰로즈류, 젤라틴 폴리비닐피롤리돈 등과 같은 충전제 등을 들 수 있다.또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제등도 포함될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등을 들 수 있는데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.The solid preparations for oral administration include powders, tablets, pills, powders, granules, capsules and the like, which can be formulated using methods known in the art. Such a solid preparation can be used by blending at least one or more excipients in the composition or pharmaceutical composition. The excipient may be selected from the group consisting of sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, corn starch, wheat starch, rice starch and potato starch, Cellulose such as cellulose, methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose, and fillers such as gelatin polyvinylpyrrolidone. In addition to simple excipients, lubricants such as magnesium stearate and talc And the like. Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions and syrups. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, .
상기 비경구 투여용 제제의 경우에는 주사제, 크림제, 로션제, 외용연고제, 오일제, 보습제, 겔제, 에어로졸 및 비강 흡입제의 형태로 당업계에 공지된 방법으로 제형화할 수 있다. 이들 제형은 모든 제약 화학에 일반적으로 공지된 처방서인 문헌(Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, Easton, PA, 1995)에 기재되어 있다. In the case of the parenteral administration preparation, it can be formulated by a method known in the art in the form of injections, creams, lotions, external ointments, oil agents, moisturizers, gels, aerosols and nasal inhalers. These formulations are described in Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, Easton, Pa., 1995, which is a commonly known formulary for all pharmaceutical chemistries.
본 발명의 일 실시형태에 따르면, 상기 심혈관계 질환 치료, 예방 또는 개선용 조성물 또는 약학적 조성물은 제조, 취급 및 보관이 용이하도록 환의 형태로 제조되는 것이 바람직하다. According to one embodiment of the present invention, it is preferable that the composition or the pharmaceutical composition for treating, preventing or ameliorating the cardiovascular diseases is manufactured in the form of a ring so as to facilitate the preparation, handling and storage.
본 발명의 다른 양태에 따르면, 상기 환 형태의 조성물의 제조방법은 버드나무 변이종 및 서목태를 각각 분쇄하여 분쇄물을 얻는 단계(1공정); 상기 1공정의 각 분쇄물을 서로 혼합하고, 상기 혼합물에 솔잎 내지 송순 발효액을 섞어 반죽하는 단계(2공정); 및 상기 2공정의 반죽으로 환을 만들어 건조하는 단계(3공정);를 포함한다. According to another aspect of the present invention, there is provided a method for producing a composition in the form of a ring, comprising the steps of (1) obtaining a ground material by pulverizing a willow variant and a seedling, respectively; Mixing the respective pulverized products of the one step with each other and kneading the mixture with a pine needle or a pine needle fermentation liquid (step 2); And a step of drying the kneaded dough of the two steps (step 3).
조성물 또는 약학적 조성물의 투여량은 치료 받을 대상의 연령, 성별, 체중, 치료할 특정 질환 또는 병리 상태, 실환 또는 병리 상태의 심각도, 투여 경로 및 처방자의 판단에 따라 달라질 수 있다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있으며, 일반적으로 투여량은 0.01mg/kg/일 내지 대략 2000mg/kg/일의 범위일 수 있다. 보다 바람직한 투여량은 0.2mg/kg/일 내지 500mg/kg/일일 수 있다. 투여는 하루에 한 번 투여할 수도 있고, 수 회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로도 본 발명의 범위를 한정하는 것은 아니다. The dosage of the composition or pharmaceutical composition may vary depending on the age, sex, weight of the subject to be treated, the specific disease or condition to be treated, the severity of the clinical or pathological condition, the route of administration and the judgment of the prescriber. Dosage determinations based on these factors are within the level of ordinary skill in the art, and dosages may generally range from 0.01 mg / kg / day to approximately 2000 mg / kg / day. A more preferred dosage may be from 0.2 mg / kg / day to 500 mg / kg / day. The administration may be carried out once a day or several times. The dose is not intended to limit the scope of the invention in any way.
본 발명의 일 실시형태에 따르면, 전술한 버드나무 변이종의 생약성분을 포함하는 조성물은 심혈관계 질환 개선용 식품 조성물일 수 있다.According to one embodiment of the present invention, the composition comprising the willow variant herbal composition described above may be a food composition for improving cardiovascular diseases.
상기 심혈관계 질환 개선용식품 조성물은 정제, 캡슐제, 환제 또는 액제 등의 형태를 포함할 수 있으며, 식품으로는 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강기능성 식품류 등을 들 수 있다. The food composition for improving cardiovascular diseases may include forms such as tablets, capsules, pills, and liquids. Examples of foods include various foods, beverages, gums, tea, vitamin complexes, and health functional foods.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당 업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다. 이하의 실시예 및 비교예에서 함량을 나타내는 "%" 및 "부"는 특별히 언급하지 않는 한 중량 기준이다. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the inventions. , And it is natural that such variations and modifications fall within the scope of the appended claims. In the following Examples and Comparative Examples, "%" and "part" representing the contents are by weight unless otherwise specified.
실시예Example : 심혈관계 질환의 치료, 예방 또는 개선용 조성물의 제조: Preparation of compositions for the treatment, prevention or amelioration of cardiovascular diseases
본 발명의 버드나무 변이종(꽃잎버들)을 포함하는 심혈관계 질환의치료, 예방 또는 개선용 조성물을 제조하였다. 이 때, 버드나무 변이종은 충주시 앙성면 중전리 지역에서 자생하고 있는 것을 사용하였으며, 도 1에서 보이는 바와 같이 잎의 형태에 변이가 일어난버드나무의 잔가지, 나무껍질 및 잎을 그 원료로 사용하였다. A composition for the treatment, prevention or amelioration of a cardiovascular disease comprising Willow variant (petal weevil) of the present invention was prepared. At that time, the willow mutant was used as the raw material of the willow tree, the bark and the leaves of the willow tree in which the shape of the leaves was changed as shown in Fig. 1.
솔잎 내지 송순의 발효액은 1년 미만의 것을 채집하여 사용하였으며, 채취한 솔잎 및 송순을 잘게 썰고, 상기 솔잎 및 송순의 혼합 생약에 설탕을 상기 혼합 생약과 동일한 중량으로 넣은 후, 설탕이 다 녹을 때까지 잘 저어주고 3개월 이상 발효시켰다. 발효시킨 발효액을 고운 천으로 걸러 송진가루를 걸러내고 솔잎 및 송순의 발효액을 확보하였다. The fermented broth of pine needle or pine needle was collected and used for less than one year. The pine needle and pine needle were cut into small pieces, and sugar was added to the pine needle and pine cone in the same weight as the mixed preparation, And fermented for more than 3 months. The fermented fermentation broth was filtered with a fine cloth to filter out the pine root powder and to secure a fermentation broth of pine needles and pine nuts.
그 외에 사용되는 버드나무 변이종(줄기, 가지 및 잎), 서목태, 산사자 및 삼채는 각각 잘게 분쇄하여 준비하였다. Other varieties of willow (stems, branches and leaves), Seomyo-tai, hermit crab and three-pods were prepared by grinding finely.
이와 같이 준비된 재료를 하기 표 1에 기재된 중량비율을 바탕으로 혼합하여, 반죽한 후 작은 환의 형태로 만들어 건조시킴으로써 환제를 제조하였다(도 3 참조). The prepared materials were mixed on the basis of the weight ratios shown in Table 1 below, kneaded, and then shaped into small rings and dried to prepare pills (see Fig. 3).
비교예Comparative Example
비교예Comparative Example 1 내지 2: 변이가 일어나지 않은 버드나무를 포함하는 조성물의 제조 1 to 2: Preparation of a composition comprising willow with no mutation
변이가 일어나지 않은 버드나무를 포함하는 조성물을 제조하였다. 이 때, 버드나무는 충주시 앙성면 중전리 지역에서 자생하고 있는 것을 사용하였으며, 도 2에서 보이는 바와 같이 잎의 형태에 변이가 일어나지 않은 버드나무의 가지, 줄기 및 잎 부분을 그 원료로 사용하였다. A composition comprising willow without mutation was prepared. At that time, the willow was used as a raw material which was naturally grown in the Chungju area, Anseong-myeon area, and the branches, stem and leaf parts of the willow, which did not have any mutation in the shape of the leaves, were used as raw materials.
그 외 성분들에 대한 준비 및 제조방법은 상기 실시예와 동일하게 하였으며, 구체적인 구성 및 함량은 하기 표 2와 같이 하였다.Preparation and preparation of the other components were the same as those of the above examples, and the specific composition and content thereof were as shown in Table 2 below.
비교예Comparative Example 3 내지 5: 버드나무의 생약성분을 포함하지 않는 조성물의 제조 3 to 5: Preparation of a composition which does not contain herbal ingredients of willow
버드나무의 생약성분을 포함하지 않는 조성물을 제조하였다. A composition not containing the herbal ingredients of willow was prepared.
그 외 성분들에 대한 준비 및 제조방법은 상기 실시예와 동일하게 하였으며, 구체적인 구성 및 함량은 하기 표 2와 같이 하였다. Preparation and preparation of the other components were the same as those of the above examples, and the specific composition and content thereof were as shown in Table 2 below.
(변이 ×)Bud tree
(Mutation x)
실험예Experimental Example 1: 혈압강하효과 실험 1: blood pressure lowering effect experiment
고혈압 증상을 갖고 있는 50대 남성 10명에게 혈압강하효과 실험을 실시하였다. Ten men in their 50s with hypertensive symptoms were tested for hypotensive effects.
상기 실시예 1 내지 5 및 비교예 1 내지 5에서 제조된 환제제의 조성물을 10명의 실험대상자들에게 각각 한 종류씩 나눠 준 후 하루에 100알(몇 번에 걸쳐 나눠먹을 수도 있고, 한번에 먹을 수도 있으나 이는 실험 대상자들의 편의대로 진행하도록 하였음)씩 물과 함께 섭취하도록 하였다. 본 실험은 4주간 실시하였으며, 환제제의 조성물을 섭취하기 시작한 후 1주일이 경과하는 시점의 오전 9시에 수축기 혈압과 이완기 혈압을 측정하여, 조성물을 섭취하기 전의 혈압과 비교하였다. 본 실험결과는 하기 표 3에 기재하였으며, 기재된 측정 값은 소수점 첫째 자리에서 반올림된 것이다. The composition of the pills prepared in Examples 1 to 5 and Comparative Examples 1 to 5 was distributed to each of the 10 subjects, and one egg per 100 eggs per day (divided into several times, But they were allowed to proceed according to the convenience of the subjects). This experiment was carried out for 4 weeks. Systolic and diastolic blood pressures were measured at 9:00 am one week after the start of the composition of the pills, and the blood pressure was compared with that before the composition was ingested. The results of this experiment are shown in Table 3 below and the measured values are rounded off to the first decimal place.
상기 표 3을 참고하면, 본 발명의 버드나무 변이종(꽃잎버들)의 생약성분을 포함하는 조성물의 경우(실시예 1 내지 5), 변이되지 않은 버드나무의 생약성분을 포함하는 경우(비교예 1내지 2)나 어떠한 버드나무의 생약성분도 포함하지 않는 경우(비교예 3 내지 5)보다 혈압강하 효과가 보다 우수한 것을 확인하였다. In the case of the composition containing the herbal composition of willow varieties (petiole) of the present invention (Examples 1 to 5) and the herbal composition of the willow without mutation (Comparative Example 1 (2) or no weeds of any willow (Comparative Examples 3 to 5).
실험예Experimental Example 2: 부정맥 증상 개선 효과 실험 2: Experiments on the improvement of arrhythmia symptoms
3년 이상 부정맥 증상(이유 없는 두근거림, 통증, 불쾌감 등)을 겪고 있는 50 ~ 70대 연령의 남성 총 50명을 선정한 후, 각 5명씩 총 10그룹으로 분리하였다. 각 그룹별로 상기 실시예 1 내지 5 및 비교예 1 내지 5에서 제조된 환제제의 조성물을 각각 섭취하도록 하였다. 실험은 총 6개월간 진행되었으며, 매일 하루에 100알(몇 번에 걸쳐 나눠먹을 수도 있고, 한번에 먹을 수도 있으나 이는 실험 대상자들의 편의대로 진행하도록 하였음) 꾸준히 섭취하도록 하였다. 6개월 후 부정맥 증상이 개선된 정도를 1 내지 10점의 점수 내에서 개선 정도가 클수록 높은 점수를 기재하도록 하였으며, 각 그룹별 평균값을 하기 표 4에 기재하였다. A total of 50 men aged 50 to 70 years who were suffering from arrhythmia (unexplained irritability, pain, discomfort, etc.) for more than 3 years were selected and divided into 10 groups of 5 each. The composition of each of the pills prepared in Examples 1 to 5 and Comparative Examples 1 to 5 was taken by each group. The experiment was carried out for a total of 6 months, and 100 eggs a day (divided several times, could be eaten at one time, but this was done at the convenience of the subjects) was steadily ingested. At 6 months, the degree of improvement in arrhythmia was graded from 1 to 10, and the higher the improvement, the higher the score, and the average value of each group was shown in Table 4 below.
상기 표 4를 참고하면, 본 발명의 버드나무 변이종의 생약성분을 포함하는 경우(실시예 1 내지 5), 변이되지 않은 버드나무의 생약성분을 포함하는 경우(비교예 1 내지 2)나 어떠한 버드나무의 생약성분도 포함하지 않는 경우(비교예 3 내지 5)보다 부정맥 증상 개선 효과가 보다 우수한 것을 확인할 수 있었다.The results are shown in Table 4. The results are shown in Table 4. The results are shown in Table 4. The results are shown in Table 4. The results are shown in Table 4, It was confirmed that the effect of improving the arrhythmia symptom was better than the case of not containing the herbal medicine ingredient of the tree (Comparative Examples 3 to 5).
실험예Experimental Example 3: 혈소판 응집 개선 실험(동물실험) 3: Platelet aggregation improvement experiment (animal experiment)
실험동물은 200g 정도의 흰쥐(Sprague Dawley male, (주)대한바이오링크)를 사용하였으며, 각 실험동물은 5일 동안 시판 사료(상품명: 실험동물 쥐 사료용 5057, 제조사명: 퓨리나코리아)를 급여하여 환경에 적응시킨 후 실험에 사용하였다.Each experimental animal was fed with a commercially available feed (trade name: 5057 for experimental animal rat feed, manufactured by Purina Korea) for about 200 g, and each experimental animal was fed with 200 g of sprague dawley male After adaptation to the environment, it was used in the experiment.
실험군은 4군으로 분류하였으며, 상기 흰쥐 10마리에게 상기한 일반 고형사료를 곱게 간 정상식이를 급여하며 이를 대조군(1군)으로 하였다. 다른 흰쥐 10마리에게는 상기 정상식이와 함께 상기 실시예 1에서 제조된 환제의 조성물을 분쇄하여 경구투여 하였으며(2군), 다른 흰쥐 10마리에게는 상기 정상식이와 함께 상기 비교예 1에서 제조된 환제의 조성물을 분쇄하여 경구투여 하였고(3군), 다른 흰쥐 10마리에게는 상기 정상식이와 함께 상기 비교예 4에서 제조된 환제의 조성물을 분쇄하여 경구투여(4군)하여 2주간 실험을 수행하였다. The experimental group was divided into 4 groups. Ten normal rats were fed a normal diet supplemented with the above-mentioned general solid diet, and the control group (group 1) was used. Ten rats of other rats were orally administrated with the above-mentioned normal diet together with the composition of the pills prepared in Example 1 (Group 2), and 10 rats of other rats were fed with the normal diet and the pills prepared in Comparative Example 1 The composition was pulverized and administered orally (Group 3). Ten rats of other rats were orally administered (group 4) with the above-mentioned normal diet and pulverized with the composition of the pills prepared in Comparative Example 4 for 2 weeks.
사육환경으로서 온도 22 ± 2.0℃, 습도 55 ± 5.0%를 유지하였고, 조명주기는 12시간으로 조절하였으며, 식이는 매일 오전 10 ~ 11시 사이에 물과 함께 공급하였고, 식이량은 식이를 공급할 때마다 측정하였다. 각 4군의 식이 조성은 하기 표 5와 같다. The temperature was maintained at 22 ± 2.0 ℃ and the humidity was 55 ± 5.0% and the illumination period was adjusted to 12 hours. The diet was supplied with water between 10 am and 11 am daily. . The dietary composition of each of the four groups is shown in Table 5 below.
(경구투여량)1) Composition
(Oral dose) 1)
실험동물은 희생시키기 전 12시간 동안 절식시킨 후 디에틸에테르로 마취시켜 복부대동맥으로부터 신선한 혈액을 채취하여 전혈 혈소판 응집능 분석에 사용하였으며, 항응고제로는 시트르산 염(sodium citrate)을 사용하였다.Experimental animals were fasted for 12 hours before sacrifice and then anesthetized with diethyl ether. Fresh blood was collected from the abdominal aorta and used for analysis of whole blood platelet aggregation ability. Sodium citrate was used as an anticoagulant.
혈소판 응집 활성은 혈소판 응집계(platelet aggregometer, Chrono-log Co., USA)를 이용하여 측정하였는데, 전혈을 이용한 전기전도도 측정방법(impedance method)을 적용하였다. 총 40마리 실험동물의 복부대동맥으로부터 조심스럽게 신선한 혈액을 채취하여 콜라겐으로 유도된 혈소판 응집 테스트(collagen-induced platelet aggregation test)를 수행하였다. The platelet aggregation activity was measured using a platelet aggregometer (Chrono-log Co., USA), and an electrical impedance measurement method using whole blood was applied. Carefully fresh blood was drawn from the abdominal aorta of a total of 40 animals to perform a collagen-induced platelet aggregation test.
혈소판 응집 활성은 실리콘 코팅된 큐벳(silicone-coated coagulated cuvette)을 미리 예열시켜 생리식염수 0.45ml를 교반 막대(stirrer bar)와 함께 잘 섞은 후 37℃에서 3분간 가온시켰다. 여기에 콜라겐(1mg/ml)를 첨가한 후 혈소판 응집계를 이용한 전기유도법(impedance)으로 혈소판 응집능을 측정하였으며, 그 결과를 하기 표 6에 기재하였다. The platelet aggregation activity was prewarmed with a silicone-coated coagulated cuvette and 0.45 ml of physiological saline was mixed well with a stirrer bar and heated at 37 ° C for 3 minutes. After adding collagen (1 mg / ml) thereto, the platelet aggregation ability was measured by an electric induction method using a platelet aggregation system. The results are shown in Table 6 below.
상기 표 6을 참고하면, 본 발명의 버드나무 변이종의 생약성분을 포함하는 조성물을 섭취하는 경우(2군, 실시예 1), 변이가 일어나지 않은 버드나무의 생약성분을 포함하는 조성물을 섭취하는 경우(3군, 비교예 1)나 어떠한 버드나무의 생약성분도 포함하지 않는 경우(4군, 비교예 4)보다 혈소판 응집개선효과가 보다 우수함을 확인하였다. 즉, 버드나무 변이종의 생약성분을 포함하는 조성물을 섭취하는 경우(2군, 실시예 1) 혈소판 응집개선효과가 우수하여 혈전의 형성을 효과적으로 저해할 수 있으며, 이로 인해 발생하는 심혈관계 질환(협심증 등)을 개선 또는 치료할 수 있을 것으로 사료된다. When the composition containing the herbal composition of willow variant of the present invention is ingested (Group 2, Example 1), when a composition containing a herbal composition of a willow tree in which mutation has not occurred is ingested (Group 3, comparative example 1) and the case where no herbal composition of willow was included (group 4, comparative example 4). That is, when a composition containing a herbal composition of willow variant is ingested (Group 2, Example 1), it is possible to effectively inhibit the formation of thrombus due to the excellent effect of improving platelet aggregation, and the resulting cardiovascular disease Or the like) can be improved or treated.
Claims (15)
고혈압, 부정맥 및 협심증으로 이루어진 군으로부터 선택되는 심혈관계 질환의 치료, 예방 또는 개선용 조성물.Characterized in that it comprises a willow variant herbal composition selected from the group consisting of a natural part itself of a willow variegate in the form of a petal willow, a dried matter thereof and an extract thereof, further comprising a pine needle leaf,
Hypertension, arrhythmia, and angina pectoris. ≪ / RTI >
상기 버드나무 변이종의 생약성분의 함량은 이를 포함하는 조성물 전체 100중량%에 대하여, 40 내지 70중량%로 포함되는 것을 특징으로 하는 조성물.The method according to claim 1,
Wherein the content of the herbal composition of willow variant is in the range of 40 to 70% by weight based on 100% by weight of the total composition.
상기 솔잎 및 송순은 1년 미만의 솔잎 및 송순인 것을 특징으로 하는 조성물.The method according to claim 1,
Wherein the pine needles and pine cones are pine leaves and pine cones less than one year old.
상기 솔잎 및 송순 발효액은 솔잎 및 송순과 설탕의 혼합물의 발효액으로부터 송진이 제거된 것임을 특징으로 하는 조성물.The method according to claim 1,
Wherein the pine needles and the pine cones are obtained by removing the pine needles from the pine needles and the mixture of pine cones and sugar.
상기 솔잎 및 송순 발효액의 함량은 이를 포함하는 조성물 전체 100중량%에 대하여, 10 내지 25중량%로 포함되는 것을 특징으로 하는 조성물.The method according to claim 1,
Wherein the content of the pine needle and the ginseng fermentation broth is 10 to 25% by weight based on 100% by weight of the total composition.
상기 서목태의 생약성분의 함량은 이를 포함하는 조성물 전체 100중량%에 대하여, 10 내지 25중량%로 포함되는 것을 특징으로 하는 조성물.The method according to claim 1,
The composition according to claim 1, wherein the content of the herbal composition is 10 to 25% by weight based on 100% by weight of the composition.
상기 조성물은 산사자 및 삼채로 이루어진 군으로부터 선택되는 하나 이상의 생약 성분을 더 포함하는 것을 특징으로 하는 조성물. The method according to claim 1,
Wherein said composition further comprises one or more herbal ingredients selected from the group consisting of sperm and triplets.
상기 산사자의 생약성분의 함량은 이를 포함하는 조성물 전체 100중량%에 대하여, 10 내지 15중량%로 포함되는 것을 특징으로 하는 조성물.9. The method of claim 8,
Wherein the content of the herbicidal component of the marine herb is contained in an amount of 10 to 15% by weight based on 100% by weight of the total composition.
상기 삼채의 생약성분의 함량은 이를 포함하는 조성물 전체 100중량%에 대하여, 10 내지 15중량%로 포함되는 것을 특징으로 하는 조성물.9. The method of claim 8,
Characterized in that the content of the herbal composition of the triplex is in the range of 10 to 15% by weight, based on 100% by weight of the total composition.
상기 조성물은 익모초, 겨우살이, 목이, 소나무잔나비버섯 및 발아흑미로 이루어진 군으로부터 선택되는 하나 이상의 생약성분을 더 포함하는 것을 특징으로 하는 조성물.The method according to claim 1,
Wherein said composition further comprises one or more herbal ingredients selected from the group consisting of motherwort, mistletoe, throat, pine mushroom and germinated brown rice.
상기 조성물은 심혈관계 질환의 치료 또는 예방용이고, 약학적 조성물인 것을 특징으로 하는 조성물.12. The method according to any one of claims 1 to 11,
Wherein said composition is for the treatment or prevention of cardiovascular diseases and is a pharmaceutical composition.
상기 조성물은 심혈관계 질환의 개선용이고, 식품 조성물인 것을 특징으로 하는 조성물.12. The method according to any one of claims 1 to 11,
Wherein the composition is for improving cardiovascular diseases and is a food composition.
상기 조성물은 환제의 형태인 것을 특징으로 하는 조성물.12. The method according to any one of claims 1 to 11,
Wherein the composition is in the form of a pill.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170072519A KR101797993B1 (en) | 2017-06-09 | 2017-06-09 | Composition comprising crude drug of willow variant for treating, preventing or improvingcardiovascular disease |
| PCT/KR2018/006463 WO2018226038A1 (en) | 2017-06-09 | 2018-06-07 | Composition for treating, preventing, or alleviating cardiovascular disease including crude drug component of willow variant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170072519A KR101797993B1 (en) | 2017-06-09 | 2017-06-09 | Composition comprising crude drug of willow variant for treating, preventing or improvingcardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101797993B1 true KR101797993B1 (en) | 2017-12-12 |
Family
ID=60943934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170072519A KR101797993B1 (en) | 2017-06-09 | 2017-06-09 | Composition comprising crude drug of willow variant for treating, preventing or improvingcardiovascular disease |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101797993B1 (en) |
| WO (1) | WO2018226038A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018226038A1 (en) * | 2017-06-09 | 2018-12-13 | 조전호 | Composition for treating, preventing, or alleviating cardiovascular disease including crude drug component of willow variant |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100826672B1 (en) | 2006-11-06 | 2008-05-02 | 이완범 | A manufacturing method of healthy drink using a mulberry tree and a willow and healthy drink thereby |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100319397B1 (en) * | 1999-07-12 | 2002-01-05 | 남 승 우 | Anti-Thrombotic and Anti-Hypercholestemic Composition Which Comprises Plant Extracts as an Active Ingredient |
| KR20090132899A (en) * | 2008-06-23 | 2009-12-31 | 조선대학교산학협력단 | Fermentation solution of pine tree leaves for improvement of blood circulation |
| KR20120092444A (en) * | 2011-02-11 | 2012-08-21 | 재단법인 한국한방산업진흥원 | A composition comprising s for cerebral apoplexy, hypertension, arteriosclerosis and hyperlipidemia, and method for preparation thereof |
| KR20160051900A (en) * | 2014-10-16 | 2016-05-12 | 전계만 | 菜 food nutrition |
| KR102010505B1 (en) * | 2014-11-18 | 2019-08-14 | 경북대학교 산학협력단 | Anti-thrombotic composition comprising phenol compound |
| KR20160073566A (en) * | 2014-12-17 | 2016-06-27 | 재단법인 포항테크노파크 | The pharmaceutical composition comprising the complex extract for preventing or treating obesity, hyperlipidemia and fatty liver |
| KR101797993B1 (en) * | 2017-06-09 | 2017-12-12 | 조전호 | Composition comprising crude drug of willow variant for treating, preventing or improvingcardiovascular disease |
-
2017
- 2017-06-09 KR KR1020170072519A patent/KR101797993B1/en active IP Right Grant
-
2018
- 2018-06-07 WO PCT/KR2018/006463 patent/WO2018226038A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100826672B1 (en) | 2006-11-06 | 2008-05-02 | 이완범 | A manufacturing method of healthy drink using a mulberry tree and a willow and healthy drink thereby |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018226038A1 (en) * | 2017-06-09 | 2018-12-13 | 조전호 | Composition for treating, preventing, or alleviating cardiovascular disease including crude drug component of willow variant |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018226038A1 (en) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104054769A (en) | Functional bread for treating cardiovascular disease and making method of functional bread | |
| EP2240193B1 (en) | Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases | |
| KR101419463B1 (en) | Herbal composition for prevention and treatment of hepatic disease | |
| KR102243873B1 (en) | Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof | |
| KR101797993B1 (en) | Composition comprising crude drug of willow variant for treating, preventing or improvingcardiovascular disease | |
| CN104800608A (en) | Traditional Chinese herbal medicine composition with hypotensive effect and application thereof | |
| KR100949482B1 (en) | Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
| WO2009091121A2 (en) | Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases | |
| CN101336965B (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
| KR101460126B1 (en) | Composition for preventing and improving sex hormone-related disease and symptoms comprising dandelion extract or dandelion containing multiple extract as an active ingredient | |
| KR101400368B1 (en) | A composition comprising boiled powder or extract of Glycine soja seed for the prevention and treatment of diabetes mellitus and diabetic complication | |
| KR20120022085A (en) | Formulations for prevention or treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts of glycine max leaves as an active ingredient | |
| CN108669450A (en) | A kind of stem of noble dendrobium loin chop and preparation method thereof | |
| KR100964603B1 (en) | Phamaceutical composition of diabetes mellitus using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
| KR20100064519A (en) | Composition comprising the extract of soybean leaves for the prevention, delay or treatment of gout | |
| KR101070476B1 (en) | Composition containing extract of black onion for prevention and treatment of Gout or Hyperuricemia | |
| EP1968401B1 (en) | Functional food composition for treating allergy, natural tea using the same and the manufacturing method thereof | |
| KR102080204B1 (en) | Clathrate compound of Schisandra chinensis extract and method for its production | |
| KR20160082568A (en) | Composition comprising Rhus verniciflua for extraction and extraction mthod of the Composition | |
| KR100865900B1 (en) | Composition comprising an extract of herbal combination(occ-i) or the powder(occ-ii) thereof for preventing and treating diabetes mellitus | |
| KR100846521B1 (en) | Composition comprising an extract of herbal combination(oca-i) or the powder(oca-ii) thereof for preventing and treating diabetes mellitus | |
| CN104304487A (en) | Health milk with efficacy of decreasing blood sugar and preparation method of health milk | |
| CN111803559B (en) | Eggplant peel composition with blood sugar reducing effect and preparation method and application thereof | |
| KR20110047585A (en) | Anti-obesity composition comprising Cordyceps militaris extracts | |
| KR102216212B1 (en) | Pharmaceutical composition comprising the fermentation product and powder of medicinal or edible natural products as an effective component for prevention or treatment of diabetes and health functional food comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |